Abstract
Objective: Periostin, an extracellular matrix protein, is related to the eosinophilic airway inflammation. There is no specific marker in allergen immunotherapy to evaluate clinical response. We aimed to investigate the serum periostin levels in the children who receive allergen immunotherapy. Materials and Methods: Sixteen patients between 8-18 years (12.7±2.8 years) with allergic rhinitis and/or asthma due to grass pollen hypersensitivity and 30 healthy subjects (11.7±2.6 years) were included. Demographic data, eosinophil counts, skin prick tests and the specific IgE levels of the patients are recorded. Symptom scores, visual analog scales, medication scores were determined and the serum periostin levels were measured in the beginning, 4th and 12th months of the allergen immunotherapy. Results: The symptom scores for rhinitis in the 4th month showed significant improvements in all of the patients (p<0.05). Nine patients with allergic rhinitis accompanied by asthma, showed significant improvements in 12th month symptom score for asthma (p=0.018). A significant correlation was detected between the initial serum periostin levels and the symptom scores for the eye (r=0.668, p=0.005). No significant difference was found in serum periostin levels between the patient and the control groups. There were no significant differences in serum periostin levels in 4th and 12th months compared to the ones in the beginning. Conclusion: In this study, there were no significant differences in serum periostin levels of children during the allergen immunotherapy. The association of serum periostin levels with symptom scores for the eye needs to be confirmed in more children with allergic rhinoconjunctivitis.
Highlights
Approach to treatment of allergic diseases such as allergic rhinitis and asthma involve control of allergens and triggering factors, patient education, drug therapy and immunotherapy [1]
There were no significant differences in serum periostin levels in 4th and 12th months compared to the ones in the beginning
In this study, there were no significant differences in serum periostin levels of children during the allergen immunotherapy
Summary
Approach to treatment of allergic diseases such as allergic rhinitis and asthma involve control of allergens and triggering factors, patient education, drug therapy and immunotherapy [1]. Allergen immunotherapy (AIT) is a treatment method whose effectiveness and reliability have been proven in cases where disease symptoms persist despite drug therapy and preventive care It has been used as the most effective treatment since the early 1900s to cure allergic asthma (AA), allergic rhinitis (AR) and atopic dermatitis (AD) associated with respiratory system allergic sensitivity as well as anaphylaxis caused by venom [1,2,3,4,5]. It inhibits allergic inflammation with early and late phase effects These effects involve remission of the disease in the long-term, prevention of development of new allergen sensitizations, prevention of the disease from proceeding from allergic rhinitis to asthma, and prevention of anaphylaxis in venom allergies. There are no routinely used markers to test clinical responses in allergen immunotherapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
